Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

J. E. Cortes, M. J. Egorin, F. Guilhot, M. Molimard, F. X. Mahon

Research output: Contribution to journalReview article

Abstract

Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival. However, plasma exposure to the drug from a given dosing regimen can vary widely among patients. Reasons for this may include incomplete adherence, intrinsic variations in the metabolism of imatinib, and drug-drug interactions. Data from two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response, leading to suggestions that maintaining imatinib blood concentrations above ∼1000 ng/ml might be associated with improved outcomes. In patients who do not respond as well as expected to initial imatinib treatment, measurement of trough plasma concentration could assist with decisions about whether to increase the dose. Blood-level testing may also be helpful in other clinical scenarios: for example, when poor adherence is suspected, adverse reactions are unusually severe, or there is a possible drug-drug interaction. Further work is required to confirm prospectively the link between imatinib plasma concentrations and response, and to define effective trough concentrations in different patient populations. However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML.

Original languageEnglish (US)
Pages (from-to)1537-1544
Number of pages8
JournalLeukemia
Volume23
Issue number9
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmacokinetics
Drug Interactions
Therapeutics
Pharmaceutical Preparations
Standard of Care
Imatinib Mesylate
Disease-Free Survival
Population

Keywords

  • Blood-level testing
  • Chronic myeloid leukemia
  • Imatinib
  • Pharmacodynamics
  • Pharmacokinetics
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. / Cortes, J. E.; Egorin, M. J.; Guilhot, F.; Molimard, M.; Mahon, F. X.

In: Leukemia, Vol. 23, No. 9, 01.09.2009, p. 1537-1544.

Research output: Contribution to journalReview article

Cortes, J. E. ; Egorin, M. J. ; Guilhot, F. ; Molimard, M. ; Mahon, F. X. / Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. In: Leukemia. 2009 ; Vol. 23, No. 9. pp. 1537-1544.
@article{785fd2197c56469ba37884cb5b7876ea,
title = "Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia",
abstract = "Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival. However, plasma exposure to the drug from a given dosing regimen can vary widely among patients. Reasons for this may include incomplete adherence, intrinsic variations in the metabolism of imatinib, and drug-drug interactions. Data from two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response, leading to suggestions that maintaining imatinib blood concentrations above ∼1000 ng/ml might be associated with improved outcomes. In patients who do not respond as well as expected to initial imatinib treatment, measurement of trough plasma concentration could assist with decisions about whether to increase the dose. Blood-level testing may also be helpful in other clinical scenarios: for example, when poor adherence is suspected, adverse reactions are unusually severe, or there is a possible drug-drug interaction. Further work is required to confirm prospectively the link between imatinib plasma concentrations and response, and to define effective trough concentrations in different patient populations. However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML.",
keywords = "Blood-level testing, Chronic myeloid leukemia, Imatinib, Pharmacodynamics, Pharmacokinetics, Tyrosine kinase inhibitors",
author = "Cortes, {J. E.} and Egorin, {M. J.} and F. Guilhot and M. Molimard and Mahon, {F. X.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1038/leu.2009.88",
language = "English (US)",
volume = "23",
pages = "1537--1544",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

AU - Cortes, J. E.

AU - Egorin, M. J.

AU - Guilhot, F.

AU - Molimard, M.

AU - Mahon, F. X.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival. However, plasma exposure to the drug from a given dosing regimen can vary widely among patients. Reasons for this may include incomplete adherence, intrinsic variations in the metabolism of imatinib, and drug-drug interactions. Data from two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response, leading to suggestions that maintaining imatinib blood concentrations above ∼1000 ng/ml might be associated with improved outcomes. In patients who do not respond as well as expected to initial imatinib treatment, measurement of trough plasma concentration could assist with decisions about whether to increase the dose. Blood-level testing may also be helpful in other clinical scenarios: for example, when poor adherence is suspected, adverse reactions are unusually severe, or there is a possible drug-drug interaction. Further work is required to confirm prospectively the link between imatinib plasma concentrations and response, and to define effective trough concentrations in different patient populations. However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML.

AB - Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML), inducing durable responses and prolonged progression-free survival. However, plasma exposure to the drug from a given dosing regimen can vary widely among patients. Reasons for this may include incomplete adherence, intrinsic variations in the metabolism of imatinib, and drug-drug interactions. Data from two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response, leading to suggestions that maintaining imatinib blood concentrations above ∼1000 ng/ml might be associated with improved outcomes. In patients who do not respond as well as expected to initial imatinib treatment, measurement of trough plasma concentration could assist with decisions about whether to increase the dose. Blood-level testing may also be helpful in other clinical scenarios: for example, when poor adherence is suspected, adverse reactions are unusually severe, or there is a possible drug-drug interaction. Further work is required to confirm prospectively the link between imatinib plasma concentrations and response, and to define effective trough concentrations in different patient populations. However, based on the current data, imatinib blood-level testing seems to be a useful aid when making clinical decisions in CML.

KW - Blood-level testing

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=70349329835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349329835&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.88

DO - 10.1038/leu.2009.88

M3 - Review article

C2 - 19404318

AN - SCOPUS:70349329835

VL - 23

SP - 1537

EP - 1544

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -